Regulatory
Matters |
|
Botulinum
toxins Type A and Type B |
|
Ceftriaxone |
|
Chromic
Phosphate P32 |
|
Cough
and cold medicines |
|
Dietary
supplements |
|
Erlotinib |
|
Etanercept |
|
Hydroxyzine
hydrochloride |
|
Salicylate
containing oral gels |
|
Testosterone
gel products |
|
Trastuzumab |
Safety of Medicines |
|
Aliskiren |
|
Angiotensin
converting enzyme inhibitors and angiotensin II receptor antagonists |
|
Antiepileptics |
|
Antipsychotics |
|
Atypical
antipsychotics |
|
Bevacizumab |
|
Cefaclor |
|
Clopidogrel |
|
Corticosteroids |
|
Flecainide |
|
Immunoglobulin |
|
Isotretinoin |
|
Lignocaine
with Clorhexidine |
|
Methylthioninium
chloride |
|
Non-steroidal
anti-inflammatory drugs |
|
Phosphate
containing laxatives |
|
Red
yeast rice extract |
|
Selective
serotonin reuptake inhibitors |
|
Sodium
valproate |
|
Varenicline |
Feature |
|
Advisory
Committee on Safety of Medicinal Products (ACSoMP) |